Orchestra BioMed (OBIO) Insider Jason Aryeh Buys 42,553 Shares
Jason Aryeh purchased 42,553 shares of Orchestra BioMed on June 23, 2026.
Reviewed by automated data checks against the source filing. How we make and check alerts
Jason Aryeh bought 42,553 shares of Orchestra BioMed Holdings, Inc. ($OBIO) on June 23, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $OBIO is up 6.9% after 1 week, down 9.9% after 1 month and up 34.9% to date (from the $4.04 close on Jun 23, 2026).
OBIO
Orchestra BioMed Holdings, Inc.
Key Points
- Jason Aryeh bought 42,553 shares of Orchestra BioMed Holdings, Inc. (OBIO) on June 23, 2026.
- Shares of OBIO traded at $3.98 on Friday, with a market cap of about $233.5 million.
- Analysts maintain a positive outlook, with recent price targets ranging from $10 to $20.
Get $OBIO trade alerts by text
We text you when insiders, Congress or big funds trade $OBIO. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Orchestra BioMed Holdings, Inc. alert may contain errors. Disclosures
Jason Aryeh, an insider at Orchestra BioMed Holdings, Inc. (NasdaqGM: OBIO), bought 42,553 shares of the company on June 23, 2026. The transaction did not involve a pre-arranged trading plan and was reported as a direct acquisition.
Insider Buying and Selling at Orchestra BioMed Holdings, Inc.
Jason Aryeh's recent purchase comes amid other insider activity. On June 23, 2026, Eric Fain also bought 17,327 shares. Meanwhile, on June 24, 2026, insiders including Chris Cleary, John Prosper Mack, Eric Fain, and David Pacitti sold shares totaling several thousand each, though these sales were not part of any planned trading arrangements.
Orchestra BioMed Holdings, Inc. Stock Down 35.9%
Shares of Orchestra BioMed Holdings, Inc. traded at $3.98 on Friday. The company has a market capitalization of approximately $233.5 million. Despite its negative earnings per share of -$0.95, the firm is positioned in the healthcare sector, particularly within biotechnology, and carries a beta of 0.5. The stock's 52-week range is between $2.20 and $5.42, with a 50-day moving average of $4.03 and a 200-day moving average of $3.99. Orchestra BioMed maintains a strong liquidity position with a current ratio of 7.03 and a quick ratio of 6.90, alongside a debt-to-equity ratio of 31.10.
Analysts Set New Price Targets
Analysts have shown confidence in Orchestra BioMed's potential. On May 19, 2026, B. Riley Securities maintained its 'buy' rating with a $10 price target. Similarly, HC Wainwright & Co. reiterated a 'buy' rating with the same target on May 14, 2026. Barclays also maintained a 'buy' rating, setting a higher target of $13 on May 13, 2026. Overall, the consensus target price is approximately $12.17, with six analysts contributing to this outlook.
About Orchestra BioMed Holdings, Inc.
Orchestra BioMed Holdings, Inc. is a biomedical firm based in New Hope, Pennsylvania. The company, led by CEO David P. Hochman, focuses on developing innovative medical therapies. Its key products include the Atrioventricular Interval Modulation for lowering blood pressure and the Virtue Sirolimus AngioInfusion Balloon for treating artery disease. With a workforce of 86 employees, Orchestra BioMed also collaborates with Medtronic and Terumo for various medical advancements.
Bottom Line
Jason Aryeh's purchase of Orchestra BioMed shares highlights ongoing insider interest at the company. With its strategic partnerships and innovative product pipeline, Orchestra BioMed remains a company to watch in the biotechnology sector. However, as with all 13F filings and insider transactions, these disclosures reflect past positions and may not indicate current holdings.
Related Filing Alerts
Source: Jason Aryeh's Form 4 filing on $OBIO (Jun 23, 2026). Find the original filing: OBIO Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts